Home > Resources > Whitepapers > The interoperability opportunity: Improving healthcare with an end-to-end enterprise strategy

The interoperability opportunity: Improving healthcare with an end-to-end enterprise strategy

October 4, 2018

Picture a single patient in a single ICU anywhere in this country. Ten devices are connected to that single patient, and each device is producing data every few seconds or minutes. What can this one patient and the data he or she generates tell us about the interoperability opportunity we have at hand?

Spotlight

Immunocore

Immunocore is a leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered in Oxfordshire, UK, with offices in Conshohocken, PA and Rockville, MD, US. The Company is privately held by a broad international investor base.

OTHER WHITEPAPERS

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

2022 Global Life Sciences Outlook

whitePaper | January 7, 2022

While valuations for the life sciences sector in this past year have been mixed, the underlying performance and outlook for the sector is healthy

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

whitePaper | February 15, 2023

The discovery of both CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and associated proteins, the Cas nucleases, has revolutionized the field of gene-editing.

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | August 30, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embark.